A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Public ClinicalTrials.gov record NCT01703572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Study identification
- NCT ID
- NCT01703572
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Dec 31, 2015
- Completion
- Dec 31, 2015
- Last update posted
- Sep 8, 2020
2012 – 2016
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| University of Colorado Hospital, Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| UF Health Davis Cancer Pavilion and Shands Med Plaza | Gainesville | Florida | 32608 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-7680 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Cornell University Division of Hematology and Medical Oncology | New York | New York | 10065 | — |
| NYU Clinical Cancer Center | New York | New York | 97219 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Sara Cannon Research Institute | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01703572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2020 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01703572 live on ClinicalTrials.gov.